Latest news

View all

Business article – November 19, 2026

Evaxion refocuses on cancer vaccines

Evaxion is shifting its strategy to concentrate on immuno-oncology. It will use its AI-Immunology platform to discover new cancer targets and develop cancer vaccines, and it will also make some changes to its organization.

Biotech Business – November 19, 2026

Asgard wins EUR 2.5 million EIC grant

Asgard Therapeutics has been awarded a EUR 2.5 million grant from the European Innovation Council (EIC) Accelerator to move its lead program, AT-108, toward clinical trials in 2027. The grant also makes the company eligible for up to EUR 10 million in equity investment from the EIC Fund.

Clinical Trials – November 19, 2026

First patient dosed in Cereno’s PAH trial

Cereno Scientific has dosed the first patient in EPIMODE, its global Phase IIb trial of the lead drug candidate CS1 in pulmonary arterial hypertension (PAH). This first dose formally launches the trial, which will evaluate CS1’s efficacy, optimal dose, safety, and tolerability, as well as its potential as a disease-modifying treatment.

MedTech Business – November 19, 2026

CLS teams up with German fiber specialist

Clinical Laserthermia Systems (CLS) has signed a strategic partnership agreement with Germany’s Advanced Fiber Tools (AFT) to develop medical laser products for markets beyond its current focus on neurosurgery and urology.

Pharma Business – November 19, 2026

FDA grants Medivir rare pediatric disease designation

The US Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to Medivir’s MIV-711 for the treatment of osteogenesis imperfecta (OI), a rare disorder that causes fragile bones. If the drug is eventually approved, the designation could earn Medivir a Priority Review Voucher – an asset that has sold for between USD 180 million and USD 210 million in 2026.

In a new job – November 18, 2026

Sten Sörensen leaves SynAct Pharma’s board

Sten Sörensen has resigned from the board of SynAct Pharma to focus on his executive responsibilities.

14 EUR
/month

Read the latest issue of our magazine!

Read the latest issue of our magazine!

  • The Nobel Prize: Exclusive interviews with the three laureates in Physiology or Medicine, profiles of the two laureates in Chemistry, and Nordic experts explaining both discoveries – optogenetics and chirality.
  • Forces of Change: Industry veteran Thomas Eldered on capital. Plus the state of Nordic collaboration (is it as good as we claim?), what women’s health needs to reach its full potential, what it really takes to scale up a biotech business, and the power of patients – a family whose rare disease journey led them to found a company.
  • Careers: Two paths on two continents, with shared experiences of female leadership. Aruna Nayak leads the Indian operations of a Swedish medtech company, and Lorna Knapstad is the first Executive Director of WiLD Norway.
  • My City: From cancer research in Oslo and advanced therapies in Stockholm to health design in Helsinki, deep tech in Reykjavík, and quantum technology in Copenhagen.
Subscribe now

Opinion & debate

Clinical Trials

Clinical Trials – November 19, 2026

First patient dosed in Cereno’s PAH trial

Cereno Scientific has dosed the first patient in EPIMODE, its global Phase IIb trial of the lead drug candidate CS1 in pulmonary arterial hypertension (PAH). This first dose formally launches the trial, which will evaluate CS1’s efficacy, optimal dose, safety, and tolerability, as well as its potential as a disease-modifying treatment.

Clinical Trials – November 17, 2026

Oncoinvent’s Radspherin clears first randomized safety review

Oncoinvent’s alpha radiopharmaceutical Radspherin has shown no treatment-related serious adverse events in the first interim safety analysis of its ongoing randomized Phase 2 trial in ovarian cancer.

Clinical Trials – November 10, 2026

Survodutide passes Phase 3 heart safety test

Boehringer Ingelheim’s obesity drug survodutide, licensed from Zealand Pharma, did not increase the risk of major cardiovascular events compared with placebo in the Phase 3 SYNCHRONIZE-CVOT trial. With this result, the registrational SYNCHRONIZE program in obesity is complete.

Clinical Trials – November 9, 2026

Novo’s ziltivekimab fails to cut heart events in full ZEUS data

Full results from Novo’s Phase 3 ZEUS trial confirm that the IL-6 inhibitor ziltivekimab did not reduce the risk of heart attack, stroke or cardiovascular death in people with atherosclerotic cardiovascular disease, chronic kidney disease and inflammation. The data were presented at the American Heart Association’s Scientific Sessions 2026 and published in the New England Journal of Medicine.

Clinical Trials – November 6, 2026

Second Gubra-partnered obesity drug moves into Phase 2

Boehringer Ingelheim has started Phase 2 development of BI 3034701, a potential first-in-class GLP-1/GIP/NPY2 triple receptor agonist partnered with Gubra, triggering a EUR 10 million milestone payment, Gubra said in its third-quarter trading statement. It is the second Gubra-partnered obesity program to reach Phase 2 this year, after AbbVie’s ABBV-295.

Clinical Trials – November 5, 2026

New data supports Herantis’ Phase II design

Finnish Herantis Pharma has extended the placebo-controlled period of its upcoming Phase II study of HER-096 in Parkinson’s disease. The company points to newly published evidence that smartphone-based motor assessments detect disease progression more sensitively than conventional clinical measures.

Follow Nordic Life Science news
Follow us on XFollow us on LinkedinFollow us on Bluesky

NLS Insight

Global report – May 26, 2025

Doing business in the world’s new life science powerhouse

In a sector long dominated by the US and Europe, Mainland China is now catching up in global pharma and biotechnology. 

Global report – May 14, 2025

US life sciences under Trump

While reports of federal cutbacks across the US health, life sciences, and research landscapes continue to fuel anxiety among scientists, the situation may not be as dire as people fear, according to one investor.

Sponsored content

Build a Targeted Biomarker Strategy for Your Program

Turn biological signals into meaningful development insights with a biomarker strategy tailored to your program. 

Follow Nordic Life Science news
Follow us on XFollow us on LinkedinFollow us on Bluesky

Explore topics

Upcoming events

We Value Your Privacy

This site uses cookies

We use cookies to improve your experience on our site. By clicking "accept," you agree to our use of cookies.

Read more about our privacy policy

Only necessary
Accept All
Manage Cookies

Manage Cookies

functional

The "Functional" cookie category includes cookies that are essential for the smooth operation of our website and to enhance your browsing experience. These cookies enable various functionalities that make our site more user-friendly and efficient.

market

The "Market" cookie category encompasses cookies used to analyze and improve our marketing efforts. These cookies help us understand how you interact with our website and provide us with insights to optimize our content and advertisements, ensuring they are relevant to your interests.

personal

The "Personal" cookie category includes cookies that enhance the user experience by storing information about your preferences and interactions on our site. This allows us to tailor content and recommendations to your individual needs, providing a more personalized and engaging experience.